Story: NeuroArmor – A Breakthrough in Brain Cell Protection
Episode: 1
Presenter: Deborah Kennedy
Air Date: 7th April 2024

A groundbreaking medicine born from a decade of research, with its potential to protect brain cells and change lives.

• Argenica Therapeutics is dedicated to the development of a leading-edge drug, ARG-007, designed to safeguard brain cells in the aftermath of severe brain injuries, including strokes, traumatic brain injuries (TBI), and Alzheimer's Disease.
• Argenica Therapeutics stands as one of the few global companies embarking on a Phase 2 clinical trial focusing on stroke patients. The trial aims to demonstrate the drug's efficacy in reducing brain injury resulting from strokes, marking a significant advancement in the field of neurological treatment.
• The urgency of receiving prompt medical intervention is paramount in stroke cases. Swift administration of potentially life-saving treatments is essential to safeguarding the brain, enhancing patient outcomes, and facilitating recovery.
• The creation of ARG-007 represents the culmination of over ten years of dedicated research conducted at the Perron Neuroscience Research Institute (Perron) and The University of Western Australia.
• This extensive research focused on evaluating the medicine's safety and efficacy, laying the foundation for its potential application in treating stroke and traumatic brain injury (TBI) patients.
• ARG-007 has the potential to be transformative for individuals affected by strokes and TBIs. If proven effective, it could offer life-changing benefits, providing hope for improved outcomes and quality of life for patients grappling with these debilitating conditions.

For more information, head to:
https://argenica.com.au/